DXCM DexCom, Inc.
Stock · NasdaqGS · United States · Healthcare · US2521311074
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by DexCom, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
81.18 USD
-3.89%
52-week range
81.18
Low54.11High92.59
Dividend yield—
Market cap33.0B
NowoTrade score
87 Grade A
Price history
Daily prices in USD.
Updated 06 Nov 2026 15:58. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 13 May 2022 | 79.13 | 84.42 | 79.12 | 83.68 | +7.45% | 4,758,000 | |
| 12 May 2022 | 77.40 | 80.20 | 75.65 | 77.88 | -1.09% | 4,438,000 | |
| 11 May 2022 | 81.80 | 84.49 | 78.35 | 78.74 | -3.81% | 3,912,400 | |
| 10 May 2022 | 85.15 | 86.44 | 79.68 | 81.86 | -0.78% | 3,253,200 | |
| 09 May 2022 | 85.69 | 87.14 | 80.50 | 82.50 | -6.22% | 6,014,800 | |
| 06 May 2022 | 93.05 | 93.45 | 86.92 | 87.97 | -7.22% | 5,272,400 | |
| 05 May 2022 | 100.25 | 102.21 | 93.07 | 94.82 | -6.59% | 2,924,000 | |
| 04 May 2022 | 99.34 | 102.43 | 94.49 | 101.51 | +2.69% | 3,529,200 | |
| 03 May 2022 | 101.36 | 101.88 | 98.26 | 98.85 | -2.88% | 2,788,800 | |
| 02 May 2022 | 102.24 | 103.45 | 99.38 | 101.79 | -0.35% | 2,750,000 | |
| 29 Apr 2022 | 103.10 | 107.87 | 101.31 | 102.14 | -1.13% | 5,434,400 | |
| 28 Apr 2022 | 103.75 | 104.42 | 99.57 | 103.31 | +0.05% | 4,573,200 | |
| 27 Apr 2022 | 106.36 | 107.65 | 102.75 | 103.25 | -2.47% | 2,857,600 | |
| 26 Apr 2022 | 109.07 | 109.45 | 104.94 | 105.88 | -4.29% | 2,624,800 | |
| 25 Apr 2022 | 109.99 | 112.53 | 108.84 | 110.62 | +0.42% | 2,461,200 | |
| 22 Apr 2022 | 116.72 | 116.96 | 109.86 | 110.16 | -6.72% | 2,460,400 | |
| 21 Apr 2022 | 124.78 | 125.95 | 117.55 | 118.10 | -4.83% | 1,900,800 | |
| 20 Apr 2022 | 122.93 | 125.63 | 120.75 | 124.10 | +0.94% | 2,166,400 | |
| 19 Apr 2022 | 119.47 | 124.00 | 119.47 | 122.95 | +2.32% | 1,992,000 | |
| 18 Apr 2022 | 122.47 | 123.00 | 119.03 | 120.16 | -2.33% | 1,344,000 | |
| 14 Apr 2022 | 124.85 | 125.00 | 121.88 | 123.03 | -1.34% | 1,640,800 | |
| 13 Apr 2022 | 123.40 | 125.73 | 123.37 | 124.70 | +1.71% | 1,986,400 | |
| 12 Apr 2022 | 125.29 | 127.20 | 122.13 | 122.61 | -0.42% | 2,509,600 | |
| 11 Apr 2022 | 124.69 | 125.46 | 122.50 | 123.12 | -2.67% | 1,980,000 | |
| 08 Apr 2022 | 127.50 | 128.70 | 125.47 | 126.50 | -1.27% | 1,496,000 |
Page 46 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
Key data
- Previous close
- 84.46 USD
- Market cap
- 33.0B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Medical Devices
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 23.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 19.5 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 8.1 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median | Reference |
|---|---|---|---|---|
| P/E (trailing)Price divided by the last 12 months of earnings per share: how many years of profit you pay for. Lower is cheaper. | 33.25× | Weak | 32.71× | Good up to 15× · fair up to 25× |
| P/E (forward)The same, with the profit analysts expect for the next 12 months. | 26.94× | Weak | 15.76× | Good up to 15× · fair up to 25× |
| Price / bookPrice against the accounting value of what the company owns minus what it owes. | 12.43× | Weak | 3.74× | Good up to 1.5× · fair up to 3× |
| Price / salesPrice against yearly revenue; useful when there is no profit yet. | 6.17× | Weak | 3.52× | Good up to 2× · fair up to 5× |
| EV / EBITDAWhat the whole business costs (shares plus net debt) against its operating earnings. | 21.73× | Weak | 13.54× | Good up to 10× · fair up to 15× |
| Free cash flow yieldThe cash left after investments, as a share of the market value. | 2.6% | Fair | 3% | Good from 5% · fair from 2% |
| Figure | Value | Reading | Sector median | Reference |
|---|---|---|---|---|
| Gross marginWhat is left of each sale after the direct cost of what was sold. | 63.4% | Good | 66.1% | Good from 40% · fair from 20% |
| Operating marginWhat is left of each sale after all operating costs. | 24.3% | Good | 8% | Good from 15% · fair from 8% |
| Net marginWhat is left of each sale after everything, tax included. | 19.4% | Good | 3.5% | Good from 10% · fair from 5% |
| Return on equityProfit for each euro the shareholders have invested. | 37.7% | Good | 6.4% | Good from 15% · fair from 8% |
| Return on assetsProfit for each euro of the company's assets. | 11.1% | Good | 3.9% | Good from 7% · fair from 3% |
| Figure | Value | Reading | Sector median | Reference |
|---|---|---|---|---|
| Revenue growth / yearYearly growth of revenue over the years we have figures for. | 17% | Good | 10.5% | Good from 8% · fair from 3% |
| EPS growth / yearYearly growth of earnings per share over the same years. | 36.6% | Good | 7% | Good from 8% · fair from 3% |
| Figure | Value | Reading | Sector median | Reference |
|---|---|---|---|---|
| Debt / equityHow much the company owes for each euro of its own capital. | 0.55× | Good | 0.52× | Good up to 0.8× · fair up to 1.6× |
| Net debt / EBITDAYears of operating earnings needed to pay the debt off (negative: more cash than debt). | -0.28× | Good | 1.62× | Good up to 1.5× · fair up to 3× |
| Interest coverHow many times the operating profit covers the interest on the debt. | 49.83× | Good | 3.3× | Good from 8× · fair from 3× |
| Current ratioShort-term assets against short-term debts: above 1 it can pay what is due this year. | 1.74× | Good | 2.12× | Good from 1.5× · fair from 1× |
| Figure | Value | Reading | Sector median | Reference |
|---|---|---|---|---|
| Payout of earningsThe share of the profit paid out as dividend. Under 100% it is covered by earnings. | 0% | Weak | 0% | Good up to 50% · fair up to 70% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow DXCM and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.